In vitro interaction between rifampicin and clindamycin against pathogenic coagulase-negative staphylococci

M. Arditi, R. Yogev

Research output: Contribution to journalArticlepeer-review

21 Scopus citations

Abstract

The MICs and MBCs for 90% of strains tested (MIC90 and MBC90, respectively) of rifampicin for 75 clinical isolates of pathogenic coagulase-negative staphylococci (PCNS) were 0.03 and 0.25 μg/ml, respectively, while the MIC90 and MBC90 of clindamycin were both >25 μg/ml. Although no synergy between rifampicin and clindamycin was found among the 15 strains studied by the checkerboard method, 6 of 12 selected strains showed synergy by the kill-curve method. No antagonism was observed by either method. All 30 strains rapidly developed resistance to rifampicin in vitro, and this could be prevented by the simultaneous presence of 1.0 μg of clindamycin per ml in the 24 methicillin-susceptible PCNS strains. The synergy between rifampicin and clindamycin observed in vitro for some strains of PCNS, together with the prevention of emergence of resistance to rifampicin by clindamycin, suggests that this antibiotic combination may be useful for the treatment of infections caused by methicillin-susceptible PCNS.

Original languageEnglish (US)
Pages (from-to)245-247
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume33
Issue number2
DOIs
StatePublished - 1989

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In vitro interaction between rifampicin and clindamycin against pathogenic coagulase-negative staphylococci'. Together they form a unique fingerprint.

Cite this